|
1
|
Halkia E, Kopanakis N, Nikolaou G and
Spiliotis J: Cytoreductive surgery and HIPEC for peritoneal
carcinomatosis. A review on morbidity and mortality. J BUON.
20(Suppl 1): S80–S87. 2015.PubMed/NCBI
|
|
2
|
Spych M, Serbiak B, Rychter A,
esien-Lewandowicz E, Gottwald L and Fijuth J: Post-operative
radiochemotherapy in patients with gastric cancer: one department's
experience of 56 patients. Br J Radiol. 84:457–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mizuguchi Y, Takizawa T, Yoshida H and
Uchida E: Dysregulated miRNA in progression of hepatocellular
carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016.
View Article : Google Scholar
|
|
4
|
Wang QX, Zhu YQ, Zhang H and Xiao J:
Altered MiRNA expression in gastric cancer: A systematic review and
meta-analysis. Cell Physiol Biochem. 35:933–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng X, Wang Z, Fillmore R and Xi Y:
MiR-200, a new star miRNA in human cancer. Cancer Lett.
344:166–173. 2014. View Article : Google Scholar :
|
|
7
|
Shi C and Zhang Z: The prognostic value of
the miR-200 family in ovarian cancer: A meta-analysis. Acta Obstet
Gynecol Scand. 95:505–512. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song F, Yang D, Liu B, Guo Y, Zheng H, Li
L, Wang T, Yu J, Zhao Y, Niu R, et al: Integrated microRNA network
analyses identify a poor-prognosis subtype of gastric cancer
characterized by the miR-200 family. Clin Cancer Res. 20:878–889.
2014. View Article : Google Scholar
|
|
9
|
Hurteau GJ, Spivack SD and Brock GJ:
Potential mRNA degradation targets of hsa-miR-200c, identified
using informatics and qRT-PCR. Cell Cycle. 5:1951–1956. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar S, Nag A and Mandal CC: A
comprehensive review on miR-200c, a promising cancer biomarker with
therapeutic potential. Curr Drug Targets. 16:1381–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang KC, Xi HQ, Cui JX, Shen WS, Li JY,
Wei B and Chen L: Prognostic role of miR-200c in various
malignancies: A systematic review and meta-analysis. Int J Clin Exp
Med. 8:1931–1943. 2015.PubMed/NCBI
|
|
12
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E,
Yurdusev E and Şahin Ö: miR-200c: A versatile watchdog in cancer
progression, EMT, and drug resistance. J Mol Med (Berl).
94:629–644. 2016. View Article : Google Scholar
|
|
14
|
Tan G, Qiu M, Chen H and Liu J: The
relationship between miR-200c and the progression of tumor. Chin J
Cancer Biother. 22:120–124. 2015.In Chinese.
|
|
15
|
Fan H and Ye M: Research progress of
micro-RNA200s in tumor metastasis. Chin Cancer. 21:840–844. 2012.In
Chinese.
|
|
16
|
Blanco-Calvo M, Tarrío N, Reboredo M,
Haz-Conde M, García J, Quindós M, Figueroa A, Antón-Aparicio L,
Calvo L and Valladares-Ayerbes M: Circulating levels of GDF15, MMP7
and miR-200c as a poor prognostic signature in gastric cancer.
Future Oncol. 10:1187–1202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang L, Guo F, Huo B, Lv Y, Wang Y and
Liu W: Expression and clinical significance of the microRNA-200
family in gastric cancer. Oncol Lett. 9:2317–2324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui FB, Liu Q, Li RT, Shen J, Wu PY, Yu
LX, Hu WJ, Wu FL, Jiang CP, Yue GF, et al: Enhancement of
radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli
PEG-Pep-PCL nanoparticles in gastric cancer cells. Int J
Nanomedicine. 9:2345–2358. 2014.PubMed/NCBI
|
|
19
|
Radisky DC: miR-200c at the nexus of
epithelial-mesenchymal transition, resistance to apoptosis, and the
breast cancer stem cell phenotype. Breast Cancer Res. 13:1102011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao C, Peng FH and Peng LK: MiR-200c
sensitizes clear-cell renal cell carcinoma cells to sorafenib and
imatinib by targeting heme oxygenase-1. Neoplasma. 61:680–689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Wang W, Zhang Y, Hu T and Chen Y:
The roles of miR-200c in colon cancer and associated molecular
mechanisms. Tumour Biol. 35:6475–6483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahdavinezhad A, Mousavi-Bahar SH,
Poorolajal J, Yadegarazari R, Jafari M, Shabab N and Saidijam M:
Evaluation of miR-141, miR-200c, miR-30b expression and
clinicopathological features of bladder cancer. Int J Mol Cell Med.
4:32–39. 2015.PubMed/NCBI
|
|
23
|
Tanaka S, Hosokawa M, Ueda K and Iwakawa
S: Effects of decitabine on invasion and exosomal expression of
miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer
cells. Biol Pharm Bull. 38:1272–1279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tamagawa S, Beder LB, Hotomi M, Gunduz M,
Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the
regulation of epithelial-mesenchymal transition and migration in
head and neck squamous cell carcinoma. Int J Mol Med. 33:879–886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang H, Deng M, Tang Y and Xie X, Guo J,
Kong Y, Ye F, Su Q and Xie X: miR-200b and miR-200c as prognostic
factors and mediators of gastric cancer cell progression. Clin
Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saito T, Kurashige J, Nambara S, Komatsu
H, Hirata H, Ueda M, Sakimura S, Uchi R, Takano Y, Shinden Y, et
al: A long non-coding RNA activated by transforming growth factor-β
is an independent prognostic marker of gastric cancer. Ann Surg
Oncol. 22(Suppl 3): S915–S922. 2015. View Article : Google Scholar
|
|
27
|
Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv
Y, Fan X, Sang M, Liu XD and Liu W: The downregulation of
miR-200c/141 promotes ZEB1/2 expression and gastric cancer
progression. Med Oncol. 32:4282015. View Article : Google Scholar
|
|
28
|
Ohta H, Aoyagi K, Fukaya M, Danjoh I, Ohta
A, Isohata N, Saeki N, Taniguchi H, Sakamoto H, Shimoda T, et al:
Cross talk between hedgehog and epithelial-mesenchymal transition
pathways in gastric pit cells and in diffuse-type gastric cancers.
Br J Cancer. 100:389–398. 2009. View Article : Google Scholar
|
|
29
|
Rosanò L, Cianfrocca R, Tocci P, Spinella
F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and
Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt
pathway renders ovarian cancer cells resistant to chemotherapy.
Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar
|
|
30
|
López-Mejías R, Genre F, García-Bermúdez
M, Ubilla B, Castañeda S, Llorca J, González-Juanatey C, Corrales
A, Miranda-Filloy JA, Pina T, et al: Lack of association between
ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media
thickness, carotid plaques, and cardiovascular disease in patients
with rheumatoid arthritis. Mediators Inflamm. 2014:7562792014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Low SK, Takahashi A, Cha PC, Zembutsu H,
Kamatani N, Kubo M and Nakamura Y: Genome-wide association study
for intracranial aneurysm in the Japanese population identifies
three candidate susceptible loci and a functional genetic variant
at EDNRA. Hum Mol Genet. 21:2102–2110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laurberg JR, Jensen JB, Schepeler T, Borre
M, Ørntoft TF and Dyrskjøt L: High expression of GEM and EDNRA is
associated with metastasis and poor outcome in patients with
advanced bladder cancer. BMC Cancer. 14:6382014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pflug BR, Zheng H, Udan MS, D'Antonio JM,
Marshall FF, Brooks JD and Nelson JB: Endothelin-1 promotes cell
survival in renal cell carcinoma through the ET(A) receptor. Cancer
Lett. 246:139–148. 2007. View Article : Google Scholar
|
|
34
|
Kar SP, Beesley J, Amin Al Olama A,
Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S,
Ramus SJ, Thompson DJ, et al: Genome-wide meta-analyses of breast,
ovarian and prostate cancer association studies identify multiple
new susceptibility loci shared by at least two cancer types. Cancer
Discov. 6:1052–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang S, Xiao Y, Liu Z, Yang X, Xiong X,
Zhu W, Shi H and Luo D: Network-guided genetic screening for
metastasis-related microRNA-200c in breast cancer. Tumor.
33:111–118. 2013.In Chinese.
|
